Anzeige
Mehr »
Login
Dienstag, 14.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Silber: Der unverzichtbare Akteur in Boom-Märkten!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESSWIRE
206 Leser
Artikel bewerten:
(1)

Protenus, Inc.: Protenus Granted Sixth Patent for Drug Diversion Surveillance Technology

New Patent Granted Assists Hospitals With Greater Coverage to Support Drug Diversion Prevention

BALTIMORE, MD / ACCESSWIRE / March 26, 2024 / Protenus, provider of the leading healthcare compliance analytics platform, today announced a new grant of a U.S. patent that supports its ongoing efforts to deliver drug diversion surveillance technology that enables hospitals and health systems to be more efficient and proactively eliminate risk to their organization and patients.

The new grant of U.S. Patent No. 11,923,062 is titled "Methods and Systems for Analyzing Accessing of Drug Dispensing Systems." With this patent, Protenus now holds six granted U.S. patents covering various techniques for detecting anomalous drug dispensing events. For example, the newly granted patent covers numerous techniques such as using pattern-based algorithms to identify hidden drug misappropriation events as part of an AI-driven approach.

"Our research estimates that one in 100 healthcare employees are diverting narcotics away from patient care," states Nick Culbertson, CEO and co-founder of Protenus. He continues, "Our award-winning drug diversion surveillance solution has consistently demonstrated the ability to surface diversion concerns early without inundating staff with manual processes. This new patent reflects our novel approach to bolstering our customers' diversion monitoring strategies."

Protenus now holds more than a dozen granted U.S. patents covering various key aspects of patient privacy monitoring and drug diversion surveillance technologies, along with several other pending U.S. and foreign patent applications.

Any licensing inquiries or other questions about the Protenus patent portfolio should be directed to Amy Much, Protenus' General Counsel, at amy.much@protenus.com.

About Protenus

Protenus harnesses the power of AI to provide healthcare organizations with scalable risk-reduction solutions that drive the safest patient outcomes while protecting the reputation of the organizations. We are committed to innovation, determined to reduce risk, and focused on supporting our community of employees, customers, and ultimately, patients. Empowering healthcare to eliminate risk is at the heart of all we do. Founded in 2014, Protenus was awarded Best in KLAS for both patient privacy monitoring and drug diversion surveillance solutions two years in a row (2023-2024), is a three-time winner of Forbes' America's Best Startup Employers, is a Great Place to Work®-Certified company, was named one of 2021 CBInsights Digital Health 150, one of The Best Places to Work in Healthcare by Modern Healthcare, and one of the Best Places to Work in Baltimore by the Baltimore Business Journal and the Baltimore Sun. Learn more at Protenus.com and follow us on X (Twitter) @Protenus.

Contact Information

Michelle Del Guercio
Chief Marketing Officer
michelle.delguercio@protenus.com
(410) 995-8850

SOURCE: Protenus

.

View the original press release on newswire.com.

Lithium vs. Palladium - Ist das die Chance des Jahrzehnts?
Sichern Sie sich den kostenlosen PDF-Report! So können Sie vom Boom der Rohstoffe profitieren.
Hier klicken
© 2024 ACCESSWIRE
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.